Used in the treatment of severe inflammatory conditions, particularly in autoimmune and complement-mediated diseases. It targets the C5a receptor (C5aR1) on immune cells, blocking the pro-inflammatory effects of the complement system. This helps reduce excessive inflammation, tissue damage, and immune cell activation seen in diseases such as severe COVID-19, rheumatoid arthritis, and other chronic inflammatory disorders. By inhibiting C5a signaling, it modulates the immune response without broadly suppressing immunity, offering a targeted approach in managing hyperinflammatory states. Currently under investigation in clinical trials for efficacy and safety in various immune dysregulation conditions.